Medika Natura CEO and COO Abdul Razak Mohd Isa and Mustadza Muhamad presented to international investors and distributors at The Nutritional Capital Network Investor Meeting (NCNIM) 2020.
The objective of the presentation which took place last October, was to attract international investors and distributors to invest in and distribute Medika Natura’s flagship product Labeesity®, which contains proprietary ingredient SKF7™, globally.
Authorised as a new dietary ingredient (NDIN) by the United States FDA (US FDA) in 2020, SKF7TM is also undergoing the first Phase 2 clinical trial of its kind in Malaysia and Indonesia. This same study has just been completed in India. The objective of the clinical trial is to determine the efficacy of SKF7TM in curtailing obesity to enable it to be classified and marketed as an anti-obesity botanical drug.
NCNIM is one of the leading venues for growth companies to connect with premium investors in the nutrition industries.
